DSpace at RU >

Browsing by Author Cats, A.

Full Text	Issue Date	Title	Author(s)
	2009	Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels.	Vrieling, A.; Voskuil, D.W.; Bosma, A., et al
	1987	Factors influencing the incidence of infections in Felty's syndrome	Breedveld, F.C.; Fibbe, W.E.; Hermans, J., et al
	2011	[Familial gastric cancer: diagnosis, treatment and periodic surveillance]	Kluijt, I.; Sijmons, R.H.; Hoogerbrugge, N., et al
	2008	Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.	Tol, J.; Cats, A.; Mol, L., et al
	2010	Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study.	Boparai, K.S.; Mathus-Vliegen, E.M.H.; Koornstra, J.J., et al
	2007	Is surveillance of the small bowel indicated for Lynch syndrome families?	Kate, G.L. ten; Kleibeuker, J.H.; Nagengast, F.M., et al
	2007	Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk.	Vrieling, A.; Rookus, M.A.; Kampman, E., et al
	2003	Kanker: eindigheid, zin en spiritualiteit : een samenwerkingsproject	Staps, T.; Yang, W.; Hijmans, E.J.S., et al
	2007	Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer.	Vrieling, A.; Voskuil, D.W.; Bonfrer, J.M.G., et al
	2008	No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancer.	Vrieling, A.; Rookus, M.A.; Kampman, E., et al
	2010	One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.	Vasen, H.F.; Abdirahman, M.; Brohet, R., et al
	2007	Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.	Hospers, G.; Punt, C.J.A.; Tesselaar, M.E., et al
	2005	Prevalence of adenomas among young individuals at average risk for colorectal cancer.	Jong, A.E. de; Morreau, H.; Nagengast, F.M., et al
	2008	A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.	Tol, J.; Koopman, M.; Rodenburg, C.J., et al
	2010	Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits.	Lammens, C.R.; Bleiker, E.M.A.; Aaronson, N.K., et al
	2011	Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer	Deenen, M.J.; Tol, J.; Burylo, A.M., et al
	2004	The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC.	Jong, A.E. de; Morreau, H.; Puijenbroek, M., et al
	2004	Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.	Vos tot Nederveen Cappel, W.H. de; Meulenbeld, H.J.; Kleibeuker, J.H., et al
	2006	What is the appropriate screening protocol in Lynch syndrome?	Jong, A.E. de; Nagengast, F.M.; Kleibeuker, J.H., et al